Real-world effectiveness of antipsychotic medication in relapse prevention after cannabis-induced psychosis Article Swipe
Antti Mustonen
,
Heidi Taipale
,
Alexander Denissoff
,
Venla Ellilä
,
Marta Di Forti
,
Antti Tanskanen
,
Ellenor Mittendorfer‐Rutz
,
Jari Tiihonen
,
Solja Niemelä
·
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.1192/bjp.2025.72
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.1192/bjp.2025.72
Background Cannabis use is linked to treatment non-adherence and relapses in psychotic disorders. Antipsychotic medication is effective for relapse prevention in primary psychoses, but its effectiveness after cannabis-induced psychosis (CIP) remains unclear. Aims To examine the effectiveness of antipsychotic medication for relapse prevention following the first clinically diagnosed CIP. Method A cohort of 1772 patients (84.1% men) with incident CIP was identified from the Swedish National Patient and Micro Data for Analyses of Social Insurance registers. The primary outcome was hospitalisation due to any psychotic episode. Drug use data were collected from the Prescribed Drug Register and modelled into drug use periods using the PRE2DUP method. A within-individual Cox regression model was used to study the risk of outcomes during the use of different oral or long-acting injectable (LAI) antipsychotics compared with non-use. Results The mean age at first diagnosis was 26.6 years (s.d. = 8.3). Of the cohort, 1343 (75.8%) used antipsychotics and 914 (51.3%) experienced psychosis hospitalisation during the follow-up. Any antipsychotic use was associated with a decreased risk of psychosis hospitalisation (adjusted hazard ratio (aHR) 0.75; 95% CI 0.67–0.84). Specific antipsychotics associated with decreased risk included aripiprazole LAI (aHR 0.27; 95% CI 0.14–0.51), olanzapine LAI (aHR 0.28; 95% CI 0.15–0.53), clozapine (aHR 0.55; 95% CI 0.34–0.90), oral aripiprazole (aHR 0.64; 95% CI 0.45–0.91), antipsychotic polytherapy (aHR 0.74; 95% CI 0.63–0.87) and oral olanzapine (aHR 0.81; 95% CI 0.69–0.94). Conclusions In particular, LAIs, clozapine and oral aripiprazole were associated with a decreased risk of psychosis relapse following CIP. Prescribers should consider using more LAIs for better treatment outcomes after CIP.
Related Topics
Concepts
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.1192/bjp.2025.72
- https://www.cambridge.org/core/services/aop-cambridge-core/content/view/7B72D8DD37FD96E521C7D64538C068DC/S0007125025000728a.pdf/div-class-title-real-world-effectiveness-of-antipsychotic-medication-in-relapse-prevention-after-cannabis-induced-psychosis-div.pdf
- OA Status
- hybrid
- Cited By
- 1
- References
- 44
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4410105341
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4410105341Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1192/bjp.2025.72Digital Object Identifier
- Title
-
Real-world effectiveness of antipsychotic medication in relapse prevention after cannabis-induced psychosisWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2025Year of publication
- Publication date
-
2025-05-06Full publication date if available
- Authors
-
Antti Mustonen, Heidi Taipale, Alexander Denissoff, Venla Ellilä, Marta Di Forti, Antti Tanskanen, Ellenor Mittendorfer‐Rutz, Jari Tiihonen, Solja NiemeläList of authors in order
- Landing page
-
https://doi.org/10.1192/bjp.2025.72Publisher landing page
- PDF URL
-
https://www.cambridge.org/core/services/aop-cambridge-core/content/view/7B72D8DD37FD96E521C7D64538C068DC/S0007125025000728a.pdf/div-class-title-real-world-effectiveness-of-antipsychotic-medication-in-relapse-prevention-after-cannabis-induced-psychosis-div.pdfDirect link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
hybridOpen access status per OpenAlex
- OA URL
-
https://www.cambridge.org/core/services/aop-cambridge-core/content/view/7B72D8DD37FD96E521C7D64538C068DC/S0007125025000728a.pdf/div-class-title-real-world-effectiveness-of-antipsychotic-medication-in-relapse-prevention-after-cannabis-induced-psychosis-div.pdfDirect OA link when available
- Concepts
-
Antipsychotic, Aripiprazole, Medicine, Olanzapine, Hazard ratio, Psychiatry, Psychosis, Internal medicine, Cannabis, Cohort, Clozapine, Proportional hazards model, Schizophrenia (object-oriented programming), Confidence intervalTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
1Total citation count in OpenAlex
- Citations by year (recent)
-
2025: 1Per-year citation counts (last 5 years)
- References (count)
-
44Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4410105341 |
|---|---|
| doi | https://doi.org/10.1192/bjp.2025.72 |
| ids.doi | https://doi.org/10.1192/bjp.2025.72 |
| ids.pmid | https://pubmed.ncbi.nlm.nih.gov/40326094 |
| ids.openalex | https://openalex.org/W4410105341 |
| fwci | 4.82483462 |
| type | article |
| title | Real-world effectiveness of antipsychotic medication in relapse prevention after cannabis-induced psychosis |
| biblio.issue | |
| biblio.volume | |
| biblio.last_page | 7 |
| biblio.first_page | 1 |
| topics[0].id | https://openalex.org/T10414 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 0.9998000264167786 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2736 |
| topics[0].subfield.display_name | Pharmacology |
| topics[0].display_name | Cannabis and Cannabinoid Research |
| topics[1].id | https://openalex.org/T10023 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.9983000159263611 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2738 |
| topics[1].subfield.display_name | Psychiatry and Mental health |
| topics[1].display_name | Schizophrenia research and treatment |
| topics[2].id | https://openalex.org/T10854 |
| topics[2].field.id | https://openalex.org/fields/27 |
| topics[2].field.display_name | Medicine |
| topics[2].score | 0.9965000152587891 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2738 |
| topics[2].subfield.display_name | Psychiatry and Mental health |
| topics[2].display_name | Bipolar Disorder and Treatment |
| is_xpac | False |
| apc_list | |
| apc_paid | |
| concepts[0].id | https://openalex.org/C2780494398 |
| concepts[0].level | 3 |
| concepts[0].score | 0.7863472700119019 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q208144 |
| concepts[0].display_name | Antipsychotic |
| concepts[1].id | https://openalex.org/C2780211496 |
| concepts[1].level | 3 |
| concepts[1].score | 0.7677755355834961 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q411188 |
| concepts[1].display_name | Aripiprazole |
| concepts[2].id | https://openalex.org/C71924100 |
| concepts[2].level | 0 |
| concepts[2].score | 0.723260223865509 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[2].display_name | Medicine |
| concepts[3].id | https://openalex.org/C2776619155 |
| concepts[3].level | 3 |
| concepts[3].score | 0.6997431516647339 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q201872 |
| concepts[3].display_name | Olanzapine |
| concepts[4].id | https://openalex.org/C207103383 |
| concepts[4].level | 3 |
| concepts[4].score | 0.6240863800048828 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q3930246 |
| concepts[4].display_name | Hazard ratio |
| concepts[5].id | https://openalex.org/C118552586 |
| concepts[5].level | 1 |
| concepts[5].score | 0.5822235941886902 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q7867 |
| concepts[5].display_name | Psychiatry |
| concepts[6].id | https://openalex.org/C2779727114 |
| concepts[6].level | 2 |
| concepts[6].score | 0.5794603824615479 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q170082 |
| concepts[6].display_name | Psychosis |
| concepts[7].id | https://openalex.org/C126322002 |
| concepts[7].level | 1 |
| concepts[7].score | 0.5390111804008484 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[7].display_name | Internal medicine |
| concepts[8].id | https://openalex.org/C2777056318 |
| concepts[8].level | 2 |
| concepts[8].score | 0.5349254608154297 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q79817 |
| concepts[8].display_name | Cannabis |
| concepts[9].id | https://openalex.org/C72563966 |
| concepts[9].level | 2 |
| concepts[9].score | 0.5257362127304077 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q1303415 |
| concepts[9].display_name | Cohort |
| concepts[10].id | https://openalex.org/C2780864610 |
| concepts[10].level | 3 |
| concepts[10].score | 0.47545477747917175 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q221361 |
| concepts[10].display_name | Clozapine |
| concepts[11].id | https://openalex.org/C50382708 |
| concepts[11].level | 2 |
| concepts[11].score | 0.459975004196167 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q223218 |
| concepts[11].display_name | Proportional hazards model |
| concepts[12].id | https://openalex.org/C2776412080 |
| concepts[12].level | 2 |
| concepts[12].score | 0.4041861295700073 |
| concepts[12].wikidata | https://www.wikidata.org/wiki/Q7431605 |
| concepts[12].display_name | Schizophrenia (object-oriented programming) |
| concepts[13].id | https://openalex.org/C44249647 |
| concepts[13].level | 2 |
| concepts[13].score | 0.1616601049900055 |
| concepts[13].wikidata | https://www.wikidata.org/wiki/Q208498 |
| concepts[13].display_name | Confidence interval |
| keywords[0].id | https://openalex.org/keywords/antipsychotic |
| keywords[0].score | 0.7863472700119019 |
| keywords[0].display_name | Antipsychotic |
| keywords[1].id | https://openalex.org/keywords/aripiprazole |
| keywords[1].score | 0.7677755355834961 |
| keywords[1].display_name | Aripiprazole |
| keywords[2].id | https://openalex.org/keywords/medicine |
| keywords[2].score | 0.723260223865509 |
| keywords[2].display_name | Medicine |
| keywords[3].id | https://openalex.org/keywords/olanzapine |
| keywords[3].score | 0.6997431516647339 |
| keywords[3].display_name | Olanzapine |
| keywords[4].id | https://openalex.org/keywords/hazard-ratio |
| keywords[4].score | 0.6240863800048828 |
| keywords[4].display_name | Hazard ratio |
| keywords[5].id | https://openalex.org/keywords/psychiatry |
| keywords[5].score | 0.5822235941886902 |
| keywords[5].display_name | Psychiatry |
| keywords[6].id | https://openalex.org/keywords/psychosis |
| keywords[6].score | 0.5794603824615479 |
| keywords[6].display_name | Psychosis |
| keywords[7].id | https://openalex.org/keywords/internal-medicine |
| keywords[7].score | 0.5390111804008484 |
| keywords[7].display_name | Internal medicine |
| keywords[8].id | https://openalex.org/keywords/cannabis |
| keywords[8].score | 0.5349254608154297 |
| keywords[8].display_name | Cannabis |
| keywords[9].id | https://openalex.org/keywords/cohort |
| keywords[9].score | 0.5257362127304077 |
| keywords[9].display_name | Cohort |
| keywords[10].id | https://openalex.org/keywords/clozapine |
| keywords[10].score | 0.47545477747917175 |
| keywords[10].display_name | Clozapine |
| keywords[11].id | https://openalex.org/keywords/proportional-hazards-model |
| keywords[11].score | 0.459975004196167 |
| keywords[11].display_name | Proportional hazards model |
| keywords[12].id | https://openalex.org/keywords/schizophrenia |
| keywords[12].score | 0.4041861295700073 |
| keywords[12].display_name | Schizophrenia (object-oriented programming) |
| keywords[13].id | https://openalex.org/keywords/confidence-interval |
| keywords[13].score | 0.1616601049900055 |
| keywords[13].display_name | Confidence interval |
| language | en |
| locations[0].id | doi:10.1192/bjp.2025.72 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S127936299 |
| locations[0].source.issn | 0007-1250, 1472-1465 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | False |
| locations[0].source.issn_l | 0007-1250 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | False |
| locations[0].source.display_name | The British Journal of Psychiatry |
| locations[0].source.host_organization | https://openalex.org/P4310311721 |
| locations[0].source.host_organization_name | Cambridge University Press |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310311721 |
| locations[0].license | cc-by |
| locations[0].pdf_url | https://www.cambridge.org/core/services/aop-cambridge-core/content/view/7B72D8DD37FD96E521C7D64538C068DC/S0007125025000728a.pdf/div-class-title-real-world-effectiveness-of-antipsychotic-medication-in-relapse-prevention-after-cannabis-induced-psychosis-div.pdf |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | https://openalex.org/licenses/cc-by |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | The British Journal of Psychiatry |
| locations[0].landing_page_url | https://doi.org/10.1192/bjp.2025.72 |
| locations[1].id | pmid:40326094 |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306525036 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | PubMed |
| locations[1].source.host_organization | https://openalex.org/I1299303238 |
| locations[1].source.host_organization_name | National Institutes of Health |
| locations[1].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | publishedVersion |
| locations[1].raw_type | |
| locations[1].license_id | |
| locations[1].is_accepted | True |
| locations[1].is_published | True |
| locations[1].raw_source_name | The British journal of psychiatry : the journal of mental science |
| locations[1].landing_page_url | https://pubmed.ncbi.nlm.nih.gov/40326094 |
| indexed_in | crossref, pubmed |
| authorships[0].author.id | https://openalex.org/A5071135424 |
| authorships[0].author.orcid | https://orcid.org/0000-0002-3259-2122 |
| authorships[0].author.display_name | Antti Mustonen |
| authorships[0].countries | FI, SE |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I28166907 |
| authorships[0].affiliations[0].raw_affiliation_string | Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden. |
| authorships[0].affiliations[1].institution_ids | https://openalex.org/I166825849 |
| authorships[0].affiliations[1].raw_affiliation_string | Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland. |
| authorships[0].affiliations[2].institution_ids | https://openalex.org/I175164238 |
| authorships[0].affiliations[2].raw_affiliation_string | Department of Psychiatry, Seinäjoki Central Hospital, Seinäjoki, Finland. |
| authorships[0].institutions[0].id | https://openalex.org/I175164238 |
| authorships[0].institutions[0].ror | https://ror.org/036je1b38 |
| authorships[0].institutions[0].type | education |
| authorships[0].institutions[0].lineage | https://openalex.org/I175164238 |
| authorships[0].institutions[0].country_code | FI |
| authorships[0].institutions[0].display_name | Seinäjoki University of Applied Sciences |
| authorships[0].institutions[1].id | https://openalex.org/I166825849 |
| authorships[0].institutions[1].ror | https://ror.org/033003e23 |
| authorships[0].institutions[1].type | education |
| authorships[0].institutions[1].lineage | https://openalex.org/I166825849 |
| authorships[0].institutions[1].country_code | FI |
| authorships[0].institutions[1].display_name | Tampere University |
| authorships[0].institutions[2].id | https://openalex.org/I28166907 |
| authorships[0].institutions[2].ror | https://ror.org/056d84691 |
| authorships[0].institutions[2].type | education |
| authorships[0].institutions[2].lineage | https://openalex.org/I28166907 |
| authorships[0].institutions[2].country_code | SE |
| authorships[0].institutions[2].display_name | Karolinska Institutet |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Antti Mustonen |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden., Department of Psychiatry, Seinäjoki Central Hospital, Seinäjoki, Finland., Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland. |
| authorships[1].author.id | https://openalex.org/A5063615584 |
| authorships[1].author.orcid | https://orcid.org/0000-0002-3281-934X |
| authorships[1].author.display_name | Heidi Taipale |
| authorships[1].countries | FI, SE |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I175532246 |
| authorships[1].affiliations[0].raw_affiliation_string | School of Pharmacy, University of Eastern Finland, Kuopio, Finland. |
| authorships[1].affiliations[1].institution_ids | https://openalex.org/I175532246, https://openalex.org/I2801564471 |
| authorships[1].affiliations[1].raw_affiliation_string | Department of Forensic Psychiatry, Niuvanniemi Hospital, University of Eastern Finland, Kuopio, Finland. |
| authorships[1].affiliations[2].institution_ids | https://openalex.org/I28166907 |
| authorships[1].affiliations[2].raw_affiliation_string | Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden. |
| authorships[1].institutions[0].id | https://openalex.org/I2801564471 |
| authorships[1].institutions[0].ror | https://ror.org/033c4qc49 |
| authorships[1].institutions[0].type | healthcare |
| authorships[1].institutions[0].lineage | https://openalex.org/I2801564471 |
| authorships[1].institutions[0].country_code | FI |
| authorships[1].institutions[0].display_name | Niuvanniemi Hospital |
| authorships[1].institutions[1].id | https://openalex.org/I175532246 |
| authorships[1].institutions[1].ror | https://ror.org/00cyydd11 |
| authorships[1].institutions[1].type | education |
| authorships[1].institutions[1].lineage | https://openalex.org/I175532246 |
| authorships[1].institutions[1].country_code | FI |
| authorships[1].institutions[1].display_name | University of Eastern Finland |
| authorships[1].institutions[2].id | https://openalex.org/I28166907 |
| authorships[1].institutions[2].ror | https://ror.org/056d84691 |
| authorships[1].institutions[2].type | education |
| authorships[1].institutions[2].lineage | https://openalex.org/I28166907 |
| authorships[1].institutions[2].country_code | SE |
| authorships[1].institutions[2].display_name | Karolinska Institutet |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Heidi Taipale |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden., Department of Forensic Psychiatry, Niuvanniemi Hospital, University of Eastern Finland, Kuopio, Finland., School of Pharmacy, University of Eastern Finland, Kuopio, Finland. |
| authorships[2].author.id | https://openalex.org/A5051683158 |
| authorships[2].author.orcid | https://orcid.org/0000-0001-5019-2600 |
| authorships[2].author.display_name | Alexander Denissoff |
| authorships[2].countries | FI |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I155660961 |
| authorships[2].affiliations[0].raw_affiliation_string | Department of Psychiatry, Faculty of Medicine, University of Turku, Turku, Finland. |
| authorships[2].affiliations[1].institution_ids | https://openalex.org/I2801970007 |
| authorships[2].affiliations[1].raw_affiliation_string | Addiction Psychiatry Unit, Department of Psychiatry, Turku University Hospital, Wellbeing County of South-West Finland, Turku, Finland. |
| authorships[2].institutions[0].id | https://openalex.org/I2801970007 |
| authorships[2].institutions[0].ror | https://ror.org/05dbzj528 |
| authorships[2].institutions[0].type | healthcare |
| authorships[2].institutions[0].lineage | https://openalex.org/I2801970007, https://openalex.org/I4210127022 |
| authorships[2].institutions[0].country_code | FI |
| authorships[2].institutions[0].display_name | Turku University Hospital |
| authorships[2].institutions[1].id | https://openalex.org/I155660961 |
| authorships[2].institutions[1].ror | https://ror.org/05vghhr25 |
| authorships[2].institutions[1].type | education |
| authorships[2].institutions[1].lineage | https://openalex.org/I155660961 |
| authorships[2].institutions[1].country_code | FI |
| authorships[2].institutions[1].display_name | University of Turku |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Alexander Denissoff |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Addiction Psychiatry Unit, Department of Psychiatry, Turku University Hospital, Wellbeing County of South-West Finland, Turku, Finland., Department of Psychiatry, Faculty of Medicine, University of Turku, Turku, Finland. |
| authorships[3].author.id | https://openalex.org/A5092527619 |
| authorships[3].author.orcid | https://orcid.org/0000-0002-8800-3841 |
| authorships[3].author.display_name | Venla Ellilä |
| authorships[3].countries | FI |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I155660961 |
| authorships[3].affiliations[0].raw_affiliation_string | Department of Psychiatry, Faculty of Medicine, University of Turku, Turku, Finland. |
| authorships[3].institutions[0].id | https://openalex.org/I155660961 |
| authorships[3].institutions[0].ror | https://ror.org/05vghhr25 |
| authorships[3].institutions[0].type | education |
| authorships[3].institutions[0].lineage | https://openalex.org/I155660961 |
| authorships[3].institutions[0].country_code | FI |
| authorships[3].institutions[0].display_name | University of Turku |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Venla Ellilä |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Department of Psychiatry, Faculty of Medicine, University of Turku, Turku, Finland. |
| authorships[4].author.id | https://openalex.org/A5100701393 |
| authorships[4].author.orcid | https://orcid.org/0000-0002-3218-6925 |
| authorships[4].author.display_name | Marta Di Forti |
| authorships[4].countries | GB |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I200323923 |
| authorships[4].affiliations[0].raw_affiliation_string | National Institute for Health Research (NIHR) Mental Health Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London, London, UK. |
| authorships[4].affiliations[1].institution_ids | https://openalex.org/I200323923, https://openalex.org/I4033806 |
| authorships[4].affiliations[1].raw_affiliation_string | South London and Maudsley NHS Mental Health Foundation Trust, London, UK. |
| authorships[4].affiliations[2].institution_ids | https://openalex.org/I183935753 |
| authorships[4].affiliations[2].raw_affiliation_string | Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK. |
| authorships[4].institutions[0].id | https://openalex.org/I183935753 |
| authorships[4].institutions[0].ror | https://ror.org/0220mzb33 |
| authorships[4].institutions[0].type | education |
| authorships[4].institutions[0].lineage | https://openalex.org/I124357947, https://openalex.org/I183935753 |
| authorships[4].institutions[0].country_code | GB |
| authorships[4].institutions[0].display_name | King's College London |
| authorships[4].institutions[1].id | https://openalex.org/I4033806 |
| authorships[4].institutions[1].ror | https://ror.org/04p102g25 |
| authorships[4].institutions[1].type | nonprofit |
| authorships[4].institutions[1].lineage | https://openalex.org/I4033806 |
| authorships[4].institutions[1].country_code | GB |
| authorships[4].institutions[1].display_name | Mental Health Foundation |
| authorships[4].institutions[2].id | https://openalex.org/I200323923 |
| authorships[4].institutions[2].ror | https://ror.org/015803449 |
| authorships[4].institutions[2].type | healthcare |
| authorships[4].institutions[2].lineage | https://openalex.org/I200323923 |
| authorships[4].institutions[2].country_code | GB |
| authorships[4].institutions[2].display_name | South London and Maudsley NHS Foundation Trust |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Marta Di Forti |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | National Institute for Health Research (NIHR) Mental Health Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London, London, UK., Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK., South London and Maudsley NHS Mental Health Foundation Trust, London, UK. |
| authorships[5].author.id | https://openalex.org/A5035597989 |
| authorships[5].author.orcid | https://orcid.org/0000-0002-3795-3126 |
| authorships[5].author.display_name | Antti Tanskanen |
| authorships[5].countries | FI, SE |
| authorships[5].affiliations[0].institution_ids | https://openalex.org/I175532246, https://openalex.org/I2801564471 |
| authorships[5].affiliations[0].raw_affiliation_string | Department of Forensic Psychiatry, Niuvanniemi Hospital, University of Eastern Finland, Kuopio, Finland. |
| authorships[5].affiliations[1].institution_ids | https://openalex.org/I28166907 |
| authorships[5].affiliations[1].raw_affiliation_string | Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden. |
| authorships[5].institutions[0].id | https://openalex.org/I2801564471 |
| authorships[5].institutions[0].ror | https://ror.org/033c4qc49 |
| authorships[5].institutions[0].type | healthcare |
| authorships[5].institutions[0].lineage | https://openalex.org/I2801564471 |
| authorships[5].institutions[0].country_code | FI |
| authorships[5].institutions[0].display_name | Niuvanniemi Hospital |
| authorships[5].institutions[1].id | https://openalex.org/I175532246 |
| authorships[5].institutions[1].ror | https://ror.org/00cyydd11 |
| authorships[5].institutions[1].type | education |
| authorships[5].institutions[1].lineage | https://openalex.org/I175532246 |
| authorships[5].institutions[1].country_code | FI |
| authorships[5].institutions[1].display_name | University of Eastern Finland |
| authorships[5].institutions[2].id | https://openalex.org/I28166907 |
| authorships[5].institutions[2].ror | https://ror.org/056d84691 |
| authorships[5].institutions[2].type | education |
| authorships[5].institutions[2].lineage | https://openalex.org/I28166907 |
| authorships[5].institutions[2].country_code | SE |
| authorships[5].institutions[2].display_name | Karolinska Institutet |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Antti Tanskanen |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden., Department of Forensic Psychiatry, Niuvanniemi Hospital, University of Eastern Finland, Kuopio, Finland. |
| authorships[6].author.id | https://openalex.org/A5047541131 |
| authorships[6].author.orcid | https://orcid.org/0000-0001-5227-0721 |
| authorships[6].author.display_name | Ellenor Mittendorfer‐Rutz |
| authorships[6].countries | SE |
| authorships[6].affiliations[0].institution_ids | https://openalex.org/I28166907 |
| authorships[6].affiliations[0].raw_affiliation_string | Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden. |
| authorships[6].institutions[0].id | https://openalex.org/I28166907 |
| authorships[6].institutions[0].ror | https://ror.org/056d84691 |
| authorships[6].institutions[0].type | education |
| authorships[6].institutions[0].lineage | https://openalex.org/I28166907 |
| authorships[6].institutions[0].country_code | SE |
| authorships[6].institutions[0].display_name | Karolinska Institutet |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | Ellenor Mittendorfer-Rutz |
| authorships[6].is_corresponding | False |
| authorships[6].raw_affiliation_strings | Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden. |
| authorships[7].author.id | https://openalex.org/A5072366449 |
| authorships[7].author.orcid | https://orcid.org/0000-0002-0400-6798 |
| authorships[7].author.display_name | Jari Tiihonen |
| authorships[7].countries | FI, SE |
| authorships[7].affiliations[0].institution_ids | https://openalex.org/I133731052 |
| authorships[7].affiliations[0].raw_affiliation_string | Neuroscience Center, University of Helsinki, Helsinki, Finland. |
| authorships[7].affiliations[1].raw_affiliation_string | Center for Psychiatry Research, Stockholm Region, Stockholm, Sweden. |
| authorships[7].affiliations[2].institution_ids | https://openalex.org/I28166907 |
| authorships[7].affiliations[2].raw_affiliation_string | Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden. |
| authorships[7].affiliations[3].institution_ids | https://openalex.org/I175532246, https://openalex.org/I2801564471 |
| authorships[7].affiliations[3].raw_affiliation_string | Department of Forensic Psychiatry, Niuvanniemi Hospital, University of Eastern Finland, Kuopio, Finland. |
| authorships[7].institutions[0].id | https://openalex.org/I2801564471 |
| authorships[7].institutions[0].ror | https://ror.org/033c4qc49 |
| authorships[7].institutions[0].type | healthcare |
| authorships[7].institutions[0].lineage | https://openalex.org/I2801564471 |
| authorships[7].institutions[0].country_code | FI |
| authorships[7].institutions[0].display_name | Niuvanniemi Hospital |
| authorships[7].institutions[1].id | https://openalex.org/I175532246 |
| authorships[7].institutions[1].ror | https://ror.org/00cyydd11 |
| authorships[7].institutions[1].type | education |
| authorships[7].institutions[1].lineage | https://openalex.org/I175532246 |
| authorships[7].institutions[1].country_code | FI |
| authorships[7].institutions[1].display_name | University of Eastern Finland |
| authorships[7].institutions[2].id | https://openalex.org/I133731052 |
| authorships[7].institutions[2].ror | https://ror.org/040af2s02 |
| authorships[7].institutions[2].type | education |
| authorships[7].institutions[2].lineage | https://openalex.org/I133731052 |
| authorships[7].institutions[2].country_code | FI |
| authorships[7].institutions[2].display_name | University of Helsinki |
| authorships[7].institutions[3].id | https://openalex.org/I28166907 |
| authorships[7].institutions[3].ror | https://ror.org/056d84691 |
| authorships[7].institutions[3].type | education |
| authorships[7].institutions[3].lineage | https://openalex.org/I28166907 |
| authorships[7].institutions[3].country_code | SE |
| authorships[7].institutions[3].display_name | Karolinska Institutet |
| authorships[7].author_position | middle |
| authorships[7].raw_author_name | Jari Tiihonen |
| authorships[7].is_corresponding | False |
| authorships[7].raw_affiliation_strings | Center for Psychiatry Research, Stockholm Region, Stockholm, Sweden., Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden., Department of Forensic Psychiatry, Niuvanniemi Hospital, University of Eastern Finland, Kuopio, Finland., Neuroscience Center, University of Helsinki, Helsinki, Finland. |
| authorships[8].author.id | https://openalex.org/A5006896538 |
| authorships[8].author.orcid | https://orcid.org/0000-0003-1130-9161 |
| authorships[8].author.display_name | Solja Niemelä |
| authorships[8].countries | FI |
| authorships[8].affiliations[0].institution_ids | https://openalex.org/I155660961 |
| authorships[8].affiliations[0].raw_affiliation_string | Department of Psychiatry, Faculty of Medicine, University of Turku, Turku, Finland. |
| authorships[8].affiliations[1].institution_ids | https://openalex.org/I2801970007 |
| authorships[8].affiliations[1].raw_affiliation_string | Addiction Psychiatry Unit, Department of Psychiatry, Turku University Hospital, Wellbeing County of South-West Finland, Turku, Finland. |
| authorships[8].institutions[0].id | https://openalex.org/I2801970007 |
| authorships[8].institutions[0].ror | https://ror.org/05dbzj528 |
| authorships[8].institutions[0].type | healthcare |
| authorships[8].institutions[0].lineage | https://openalex.org/I2801970007, https://openalex.org/I4210127022 |
| authorships[8].institutions[0].country_code | FI |
| authorships[8].institutions[0].display_name | Turku University Hospital |
| authorships[8].institutions[1].id | https://openalex.org/I155660961 |
| authorships[8].institutions[1].ror | https://ror.org/05vghhr25 |
| authorships[8].institutions[1].type | education |
| authorships[8].institutions[1].lineage | https://openalex.org/I155660961 |
| authorships[8].institutions[1].country_code | FI |
| authorships[8].institutions[1].display_name | University of Turku |
| authorships[8].author_position | last |
| authorships[8].raw_author_name | Solja Niemelä |
| authorships[8].is_corresponding | False |
| authorships[8].raw_affiliation_strings | Addiction Psychiatry Unit, Department of Psychiatry, Turku University Hospital, Wellbeing County of South-West Finland, Turku, Finland., Department of Psychiatry, Faculty of Medicine, University of Turku, Turku, Finland. |
| has_content.pdf | True |
| has_content.grobid_xml | True |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://www.cambridge.org/core/services/aop-cambridge-core/content/view/7B72D8DD37FD96E521C7D64538C068DC/S0007125025000728a.pdf/div-class-title-real-world-effectiveness-of-antipsychotic-medication-in-relapse-prevention-after-cannabis-induced-psychosis-div.pdf |
| open_access.oa_status | hybrid |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Real-world effectiveness of antipsychotic medication in relapse prevention after cannabis-induced psychosis |
| has_fulltext | True |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T10414 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 0.9998000264167786 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2736 |
| primary_topic.subfield.display_name | Pharmacology |
| primary_topic.display_name | Cannabis and Cannabinoid Research |
| related_works | https://openalex.org/W4311483222, https://openalex.org/W2015574399, https://openalex.org/W2979399756, https://openalex.org/W2392398171, https://openalex.org/W2378911086, https://openalex.org/W2374716361, https://openalex.org/W2379589816, https://openalex.org/W2009373849, https://openalex.org/W2095927831, https://openalex.org/W2378725359 |
| cited_by_count | 1 |
| counts_by_year[0].year | 2025 |
| counts_by_year[0].cited_by_count | 1 |
| locations_count | 2 |
| best_oa_location.id | doi:10.1192/bjp.2025.72 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S127936299 |
| best_oa_location.source.issn | 0007-1250, 1472-1465 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | False |
| best_oa_location.source.issn_l | 0007-1250 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | False |
| best_oa_location.source.display_name | The British Journal of Psychiatry |
| best_oa_location.source.host_organization | https://openalex.org/P4310311721 |
| best_oa_location.source.host_organization_name | Cambridge University Press |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310311721 |
| best_oa_location.license | cc-by |
| best_oa_location.pdf_url | https://www.cambridge.org/core/services/aop-cambridge-core/content/view/7B72D8DD37FD96E521C7D64538C068DC/S0007125025000728a.pdf/div-class-title-real-world-effectiveness-of-antipsychotic-medication-in-relapse-prevention-after-cannabis-induced-psychosis-div.pdf |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | The British Journal of Psychiatry |
| best_oa_location.landing_page_url | https://doi.org/10.1192/bjp.2025.72 |
| primary_location.id | doi:10.1192/bjp.2025.72 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S127936299 |
| primary_location.source.issn | 0007-1250, 1472-1465 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | False |
| primary_location.source.issn_l | 0007-1250 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | False |
| primary_location.source.display_name | The British Journal of Psychiatry |
| primary_location.source.host_organization | https://openalex.org/P4310311721 |
| primary_location.source.host_organization_name | Cambridge University Press |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310311721 |
| primary_location.license | cc-by |
| primary_location.pdf_url | https://www.cambridge.org/core/services/aop-cambridge-core/content/view/7B72D8DD37FD96E521C7D64538C068DC/S0007125025000728a.pdf/div-class-title-real-world-effectiveness-of-antipsychotic-medication-in-relapse-prevention-after-cannabis-induced-psychosis-div.pdf |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | https://openalex.org/licenses/cc-by |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | The British Journal of Psychiatry |
| primary_location.landing_page_url | https://doi.org/10.1192/bjp.2025.72 |
| publication_date | 2025-05-06 |
| publication_year | 2025 |
| referenced_works | https://openalex.org/W2916393779, https://openalex.org/W6860803099, https://openalex.org/W2512945539, https://openalex.org/W2887279252, https://openalex.org/W2980779999, https://openalex.org/W4394999084, https://openalex.org/W4292373143, https://openalex.org/W2290622365, https://openalex.org/W6633233630, https://openalex.org/W2900970632, https://openalex.org/W2043514212, https://openalex.org/W618764699, https://openalex.org/W4220797312, https://openalex.org/W2888509883, https://openalex.org/W3092607921, https://openalex.org/W2501603005, https://openalex.org/W2603550846, https://openalex.org/W4311204828, https://openalex.org/W4293090280, https://openalex.org/W2623053349, https://openalex.org/W2587704205, https://openalex.org/W2122519801, https://openalex.org/W4246725948, https://openalex.org/W2995126867, https://openalex.org/W1603664273, https://openalex.org/W1910190157, https://openalex.org/W1872658730, https://openalex.org/W4381547196, https://openalex.org/W2951321955, https://openalex.org/W4393214782, https://openalex.org/W2015557371, https://openalex.org/W2943577253, https://openalex.org/W2257957527, https://openalex.org/W4389309712, https://openalex.org/W6647072451, https://openalex.org/W2162942237, https://openalex.org/W4387077338, https://openalex.org/W4362070822, https://openalex.org/W2018679306, https://openalex.org/W2041031356, https://openalex.org/W2736017503, https://openalex.org/W1557478422, https://openalex.org/W1987447099, https://openalex.org/W4391311927 |
| referenced_works_count | 44 |
| abstract_inverted_index.= | 144 |
| abstract_inverted_index.A | 50, 106 |
| abstract_inverted_index.a | 168, 242 |
| abstract_inverted_index.CI | 180, 194, 201, 207, 214, 221, 229 |
| abstract_inverted_index.In | 232 |
| abstract_inverted_index.Of | 146 |
| abstract_inverted_index.To | 33 |
| abstract_inverted_index.at | 137 |
| abstract_inverted_index.in | 10, 20 |
| abstract_inverted_index.is | 3, 15 |
| abstract_inverted_index.of | 37, 52, 72, 117, 122, 171, 245 |
| abstract_inverted_index.or | 125 |
| abstract_inverted_index.to | 5, 82, 113 |
| abstract_inverted_index.914 | 154 |
| abstract_inverted_index.95% | 179, 193, 200, 206, 213, 220, 228 |
| abstract_inverted_index.Any | 162 |
| abstract_inverted_index.CIP | 59 |
| abstract_inverted_index.Cox | 108 |
| abstract_inverted_index.LAI | 190, 197 |
| abstract_inverted_index.The | 76, 134 |
| abstract_inverted_index.age | 136 |
| abstract_inverted_index.and | 8, 67, 96, 153, 223, 236 |
| abstract_inverted_index.any | 83 |
| abstract_inverted_index.but | 23 |
| abstract_inverted_index.due | 81 |
| abstract_inverted_index.for | 17, 40, 70, 256 |
| abstract_inverted_index.its | 24 |
| abstract_inverted_index.the | 35, 44, 63, 92, 103, 115, 120, 147, 160 |
| abstract_inverted_index.use | 2, 87, 100, 121, 164 |
| abstract_inverted_index.was | 60, 79, 111, 140, 165 |
| abstract_inverted_index.(aHR | 191, 198, 204, 211, 218, 226 |
| abstract_inverted_index.1343 | 149 |
| abstract_inverted_index.1772 | 53 |
| abstract_inverted_index.26.6 | 141 |
| abstract_inverted_index.Aims | 32 |
| abstract_inverted_index.CIP. | 48, 249, 261 |
| abstract_inverted_index.Data | 69 |
| abstract_inverted_index.Drug | 86, 94 |
| abstract_inverted_index.LAIs | 255 |
| abstract_inverted_index.data | 88 |
| abstract_inverted_index.drug | 99 |
| abstract_inverted_index.from | 62, 91 |
| abstract_inverted_index.into | 98 |
| abstract_inverted_index.mean | 135 |
| abstract_inverted_index.men) | 56 |
| abstract_inverted_index.more | 254 |
| abstract_inverted_index.oral | 124, 209, 224, 237 |
| abstract_inverted_index.risk | 116, 170, 187, 244 |
| abstract_inverted_index.used | 112, 151 |
| abstract_inverted_index.were | 89, 239 |
| abstract_inverted_index.with | 57, 131, 167, 185, 241 |
| abstract_inverted_index.(CIP) | 29 |
| abstract_inverted_index.(LAI) | 128 |
| abstract_inverted_index.(aHR) | 177 |
| abstract_inverted_index.(s.d. | 143 |
| abstract_inverted_index.0.27; | 192 |
| abstract_inverted_index.0.28; | 199 |
| abstract_inverted_index.0.55; | 205 |
| abstract_inverted_index.0.64; | 212 |
| abstract_inverted_index.0.74; | 219 |
| abstract_inverted_index.0.75; | 178 |
| abstract_inverted_index.0.81; | 227 |
| abstract_inverted_index.8.3). | 145 |
| abstract_inverted_index.LAIs, | 234 |
| abstract_inverted_index.Micro | 68 |
| abstract_inverted_index.after | 26, 260 |
| abstract_inverted_index.first | 45, 138 |
| abstract_inverted_index.model | 110 |
| abstract_inverted_index.ratio | 176 |
| abstract_inverted_index.study | 114 |
| abstract_inverted_index.using | 102, 253 |
| abstract_inverted_index.years | 142 |
| abstract_inverted_index.(84.1% | 55 |
| abstract_inverted_index.Method | 49 |
| abstract_inverted_index.Social | 73 |
| abstract_inverted_index.better | 257 |
| abstract_inverted_index.cohort | 51 |
| abstract_inverted_index.during | 119, 159 |
| abstract_inverted_index.hazard | 175 |
| abstract_inverted_index.linked | 4 |
| abstract_inverted_index.should | 251 |
| abstract_inverted_index.(51.3%) | 155 |
| abstract_inverted_index.(75.8%) | 150 |
| abstract_inverted_index.PRE2DUP | 104 |
| abstract_inverted_index.Patient | 66 |
| abstract_inverted_index.Results | 133 |
| abstract_inverted_index.Swedish | 64 |
| abstract_inverted_index.cohort, | 148 |
| abstract_inverted_index.examine | 34 |
| abstract_inverted_index.method. | 105 |
| abstract_inverted_index.outcome | 78 |
| abstract_inverted_index.periods | 101 |
| abstract_inverted_index.primary | 21, 77 |
| abstract_inverted_index.relapse | 18, 41, 247 |
| abstract_inverted_index.remains | 30 |
| abstract_inverted_index.Analyses | 71 |
| abstract_inverted_index.Cannabis | 1 |
| abstract_inverted_index.National | 65 |
| abstract_inverted_index.Register | 95 |
| abstract_inverted_index.Specific | 182 |
| abstract_inverted_index.compared | 130 |
| abstract_inverted_index.consider | 252 |
| abstract_inverted_index.episode. | 85 |
| abstract_inverted_index.incident | 58 |
| abstract_inverted_index.included | 188 |
| abstract_inverted_index.modelled | 97 |
| abstract_inverted_index.non-use. | 132 |
| abstract_inverted_index.outcomes | 118, 259 |
| abstract_inverted_index.patients | 54 |
| abstract_inverted_index.relapses | 9 |
| abstract_inverted_index.unclear. | 31 |
| abstract_inverted_index.(adjusted | 174 |
| abstract_inverted_index.Insurance | 74 |
| abstract_inverted_index.clozapine | 203, 235 |
| abstract_inverted_index.collected | 90 |
| abstract_inverted_index.decreased | 169, 186, 243 |
| abstract_inverted_index.diagnosed | 47 |
| abstract_inverted_index.diagnosis | 139 |
| abstract_inverted_index.different | 123 |
| abstract_inverted_index.effective | 16 |
| abstract_inverted_index.following | 43, 248 |
| abstract_inverted_index.psychosis | 28, 157, 172, 246 |
| abstract_inverted_index.psychotic | 11, 84 |
| abstract_inverted_index.treatment | 6, 258 |
| abstract_inverted_index.Background | 0 |
| abstract_inverted_index.Prescribed | 93 |
| abstract_inverted_index.associated | 166, 184, 240 |
| abstract_inverted_index.clinically | 46 |
| abstract_inverted_index.disorders. | 12 |
| abstract_inverted_index.follow-up. | 161 |
| abstract_inverted_index.identified | 61 |
| abstract_inverted_index.injectable | 127 |
| abstract_inverted_index.medication | 14, 39 |
| abstract_inverted_index.olanzapine | 196, 225 |
| abstract_inverted_index.prevention | 19, 42 |
| abstract_inverted_index.psychoses, | 22 |
| abstract_inverted_index.registers. | 75 |
| abstract_inverted_index.regression | 109 |
| abstract_inverted_index.Conclusions | 231 |
| abstract_inverted_index.Prescribers | 250 |
| abstract_inverted_index.experienced | 156 |
| abstract_inverted_index.long-acting | 126 |
| abstract_inverted_index.particular, | 233 |
| abstract_inverted_index.polytherapy | 217 |
| abstract_inverted_index.0.63–0.87) | 222 |
| abstract_inverted_index.aripiprazole | 189, 210, 238 |
| abstract_inverted_index.0.14–0.51), | 195 |
| abstract_inverted_index.0.15–0.53), | 202 |
| abstract_inverted_index.0.34–0.90), | 208 |
| abstract_inverted_index.0.45–0.91), | 215 |
| abstract_inverted_index.0.67–0.84). | 181 |
| abstract_inverted_index.0.69–0.94). | 230 |
| abstract_inverted_index.Antipsychotic | 13 |
| abstract_inverted_index.antipsychotic | 38, 163, 216 |
| abstract_inverted_index.effectiveness | 25, 36 |
| abstract_inverted_index.non-adherence | 7 |
| abstract_inverted_index.antipsychotics | 129, 152, 183 |
| abstract_inverted_index.hospitalisation | 80, 158, 173 |
| abstract_inverted_index.cannabis-induced | 27 |
| abstract_inverted_index.within-individual | 107 |
| cited_by_percentile_year.max | 95 |
| cited_by_percentile_year.min | 91 |
| countries_distinct_count | 3 |
| institutions_distinct_count | 9 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.4099999964237213 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.86254963 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | True |